Intensity Therapeutics (INTS) is trading up at $3.45 (+0.29%), as of the latest quote. It operates in the Health Care sector.
| FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| Operating income | −$7.55M | −$8.32M | −$16.6M | −$12.0M |
| Net income | −$7.58M | −$10.5M | −$16.3M | −$11.6M |
| EPS (diluted) | −$55.50 | −$34.50 | −$29.24 | −$8.56 |
| Balance sheet | ||||
| Cash and equivalents | $1.31M | $8.56M | $2.59M | $11.9M |
| Total assets | $1.76M | $17.3M | $4.78M | $14.1M |
| Total liabilities | $6.86M | $4.13M | $1.86M | $2.23M |
| Shareholders' equity | −$15.1M | $13.2M | $2.92M | $11.9M |
| Cash flow | ||||
| Operating cash flow | −$5.48M | −$7.21M | −$15.2M | −$9.23M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$3.57M | −$3.20M | −$3.39M | −$2.71M | −$2.73M | −$3.14M | −$2.53M | −$3.08M |
| Net income | −$3.51M | −$3.18M | −$3.35M | −$2.54M | −$2.67M | −$3.05M | −$2.43M | −$3.01M |
| EPS (diluted) | −$6.25 | −$5.49 | −$5.51 | −$3.36 | −$1.50 | $1.81 | −$0.96 | −$1.11 |
| Balance sheet | ||||||||
| Cash and equivalents | $2.78M | $2.59M | $929.0K | $2.22M | $7.07M | $11.9M | $10.2M | $9.53M |
| Total assets | $5.21M | $4.78M | $3.06M | $4.44M | $9.59M | $14.1M | $12.3M | $11.5M |
| Total liabilities | $2.43M | $1.86M | $2.73M | $2.26M | $2.36M | $2.23M | $2.31M | $2.31M |
| Shareholders' equity | $2.78M | $2.92M | $334.0K | $2.18M | $7.22M | $11.9M | $9.98M | $9.21M |
| Cash flow | ||||||||
| Operating cash flow | −$3.97M | −$2.67M | −$1.99M | −$2.46M | −$2.39M | −$2.40M | −$1.83M | −$2.34M |
From Intensity Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Intensity Therapeutics in our feed yet.